Opportunistic Pulmonary Infections in the Solid Organ Transplant Recipient A Focus on Drug Therapy
Opportunistic Pulmonary Infections in the Solid Organ Transplant Recipient A Focus on Drug Therapy
复制标题
DOI：
10.1097/cnq.0000000000000176
复制
发表时间：
2017-10-01
影响因子：
1.4
通讯作者：
Rendulic, TrisAnn
中科院分区：
文献类型：
--
作者：
Goetz, Megan E.;Evans, Rickey A.;Rendulic, TrisAnn
在实体器官移植受者中预防同种异体移植物排斥所需的免疫抑制增加了感染的脆弱性。由于持续的环境暴露，肺部越来越容易受到细菌，病毒和真菌机会性感染。用于治疗机会性肺部感染的药物治疗选择很少使用。这些药物通常被归类为具有特定给药说明的高风险药物，以及多种毒性。因此，在这篇文章中，我们将讨论选择肺部机会性感染及其相关的药物治疗。
Immunosuppression required to prevent allograft rejection in the solid organ transplant recipient increases vulnerability to infections. Given continuous environmental exposure, the lungs are increasingly susceptible to bacterial, viral, and fungal opportunistic infections. Drug therapy options for the treatment of opportunistic pulmonary infections are used infrequently. These medications are often classified as high risk with specific administration instructions, as well as a multitude of toxicities. Therefore, in this article, we will discuss select pulmonary opportunistic infections and their associated drug therapies.